

Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition- Christopher C. Patterson- Queen's University Belfast, United Kingdom

Christopher C. Patterson

Abstract

Aims: This article describes the methods, results and limitations of the International Diabetes Federation (IDF) Diabetes Atlas 9th edition estimates of worldwide numbers of cases of type 1 diabetes in children and adolescents. **Methods:** Most information in the published literature is in the form of incidence rates derived from registers of newly-diagnosed cases. After systematic review of the published literature and recent conference abstracts, identified studies were quality graded. If no study was available, extrapolation was used to assign a country the rate from an adjacent country with similar characteristics. Estimates of incident cases were obtained by applying incidence rates to United Nations 2019 population estimates. Estimates of prevalent cases were derived from incidence rates after making allowance for higher mortality rates in less-developed countries. **Results:** Incidence rates were available for 45% of countries (ranging from 6% in the sub-Saharan Africa region to 77% in the European region). Worldwide annual incidence estimates were 98,200 (128,900) new cases in the under 15 year (under 20 year) age-groups. Corresponding prevalence estimates were 600,900 (1,110,100) existing cases. Compared with estimates in earlier Atlas editions, numbers have increased in most IDF regions, reflecting incidence rate increases, but prevalence estimates have decreased in sub-Saharan Africa because allowance has been made for increased mortality in those with diabetes. **Conclusions:** Worldwide estimates of numbers of children and adolescents with type 1 diabetes continue to increase.

Worldwide, regional and national estimates are produced for incidence and prevalence of type 1 diabetes (T1D) in children and adolescents. Prevalence estimates for children under 15

years in the 7th and previous editions of the Atlas have been based largely on available published incidence rates, with an assumption of a prevalence to incidence ratio of 6.2 made for countries with no available age-specific incidence rates [12]. However, anecdotal and published evidence suggests that the resulting prevalence figures were unrealistically high in less developed countries where lack of access to insulin and facilities for T1D management results in high case mortality [13,14,15]. Since the 8th edition IDF Diabetes Atlas [11] worldwide estimates of incidence and prevalence of T1D in the under 15 year and under 20 year age-groups have been produced, and more realistic figures for prevalence have been provided than in previous Atlas editions by making allowance for the higher mortality rates in those with prevalent T1D. The objective of this article is to describe the methods developed for the 8th edition estimates of prevalent cases and to provide more detail and analysis of the incidence and prevalence estimates for the 9th edition.

If more than one study was available for a country, the following criteria were applied to select the most suitable: more recent studies, covering a large part of the country, including the age ranges 0-14 and 15-19 years, providing age/sex-specific rates for 0-4, 5-9, 10-14 and 15-19 year age-groups, and quality grade A. In several countries, two or more studies were judged equally suitable on these criteria and the results of these studies were combined by averaging age/sex-specific rates. All studies used in the 9th edition estimates for T1D in children and adolescents provided incidence rates rather than prevalence rates.

2.2. International Diabetes Federation The IDF divides countries into seven Regions: Africa (AFR), Europe (EUR), Middle East and North Africa (MENA), North America and Caribbean (NAC), South and Central America (SACA), South-East Asia (SEA) and Western Pacific (WP). This regional division was used throughout this

Christopher C. Patterson

Queen's University Belfast, United Kingdom, E-mail: c.patterson@qub.ac.uk

article.2.3. World Bank income group Countries were assigned an income group based on gross national income (GNI) per capita in 2018 as published in the June 2019 World Bank Income Classification[16]: low-income country (LIC) <\$1025, lower-middle-income country (LMIC) \$1026 to \$3995, upper-middle-income country (UMIC) \$3996 to \$12,735; high-income country (HIC) >\$12,735.2.4. Incidence rates for children If age-and-sex-specific incidence rates were available the direct method of standardisation was used, with the standard population having equal populations in each 5-year age/sex sub-group. If age-specific rates were not provided separately for each sex then the same rates were assumed for males and females. For countries in which no published incidence figures were available, the 0–14 year standardised incidence rate from similar countries were used instead. The choice of country from which to extrapolate was based on study quality, geographical proximity, per capita income and ethnic background. Of the selected publications, only 19 had data on incidence rates of T1D aged 15 or older. This was too small a number of studies for meaningful extrapolation to neighbouring countries (the approach used in the 0–14 year age-group). Instead, 28 publications were selected to contribute towards ratio estimates for each IDF Region. Sixteen of these studies were from the EUR Region, three from the AFR Region, one from SACA Region and two from each of the remaining four Regions. Table 1 shows the ratios obtained for each Region calculated as the average of ratios for studies from the Region with available data. The ratio of 7.0 for the AFR Region was considerably larger than the ratio for any other Region, indicative of a markedly higher incidence in the 15–19 age-group relative to the 0–14 age-group in this Region.

Nationwide, population-based prospective registries provide the best data on the incidence of T1D in childhood and adolescence, particularly if high ascertainment rates are maintained, but such studies are typically only conducted in well-resourced countries. Smaller studies can show large year to year fluctuations in T1D incidence and, where available, several years of data were used to obtain more reliable estimates. Given the widely-reported increasing T1D incidence rates in childhood, the use of data published prior to 1990 has been discontinued in the 9th edition estimates and the most up-to-date data available for each country has been used, but many of the sources in Supplementary Table 2 give rates which relate only to the 1990s. No attempt has been made to adjust these rates to reflect increases in incidence in intervening years, and neither have adjustments been made to inflate rates from registries which are known to have incomplete ascertainment. The expense of maintaining high-quality registries is considerable, and in the future it seems likely that alternative sources of incidence rate estimates will be obtained from

computerised clinical information systems and prescription or health insurance databases. As well as the use of extrapolation of incidence from a country to its neighbours, which was particularly common in AFR Region where so few countries supplied data, the use of rates from regional studies to represent whole countries is an obvious weakness, especially in countries with heterogeneous and ethnically diverse populations. Again, the availability of more publications with national coverage, particularly from less developed countries, would be the most satisfactory solution to this concern. In the previous 8th edition of the IDF Diabetes Atlas, for the first time, attempts were made to adjust the method of obtaining prevalence from incidence to take account of the well-known excess mortality in children and adolescents with T1D. An important consequence of this is that prevalence estimates for children and adolescents are no longer comparable with those provided in earlier editions of the Atlas, the lack of comparability affecting particularly the less developed countries where survival of those with T1D is poorest. The method that was used can be criticised on the basis that it requires considerable extrapolation of a relationship between excess mortality in those with T1D (as measured by the SMR) and infant mortality rate that was derived mainly from data in developed countries[4]

This work is partly presented at 52th Annual Congress on Neuroscience and stroke 2020, December 14, 2020

Christopher C. Patterson
Queen's University Belfast, United Kingdom, E-mail: c.patterson@qub.ac.uk